APLS Price Prediction Next Week
APLS Stock Price Prediction and Recommendation
News Analysis:
- Survey Insights: Physicians are increasingly using Syfovre, with expectations of steady growth over the next year. However, JP Morgan has lowered its price target to $45 due to a longer timeline for peak sales.
- Earnings Report: APLS reported a fourth-quarter loss of 29 cents per share, beating expectations, with sales up 45.2% to $212.5 million. JP Morgan maintains an Overweight rating with a $54 price target.
- Market Competition: Novartis's FDA approval for Fabhalta leaves room for Empaveli to stand out, with a commercial launch expected in late 2025.
Technical Indicators:
- RSI: 35.35 (oversold territory, potential for a bounce).
- MACD: Slightly negative, indicating bearish momentum.
- Fibonacci Levels: Resistance at $25.62, support at $23.61.
- SMA: Trading below 20 and 50-day moving averages.
Price Prediction:
Based on the oversold RSI and potential positive news, APLS is expected to trade between $24 and $26 next week, with a potential target of $25.62.
Recommendation:
Buy APLS stock at current levels, targeting $25.62, as the oversold conditions and positive news may drive a rebound.
APLS Similar Chart Price Prediction
The price of APLS is predicted to go up 48.03%, based on the high correlation periods with INSE. The similarity of these two price pattern on the periods is 98.04%.
APLS
INSE
Up: 48.03%Similarity: 98.04%
APLS Revenue Forecast
APLS EPS Forecast
APLS FAQs
What is APLS revenue forecast for next quarter？
APLS Analyst's Forecast
Anupam Rama
JP Morgan
Buy
2025-03-04
Price Target
$50 → $54
Upside
+112.06%
JPMorgan raised the firm's price target on Apellis to $54 from $50 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group post the Q4 reports.
Laura Chico
Wedbush
Hold
2025-03-03
Price Target
$30 → $29
Upside
+19.86%
Salveen Richter
Goldman Sachs
Strong Buy → Hold
2024-12-17
Price Target
$36
Upside
+5.17%
